Lymphoma Active Clinical Trials

Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date participating institutions started to open the trial. Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.

Need More Information About a Particular Clinical Trial? Contact Us

To view educational materials, click on the links provided in the Educational Materials column. To send an email to the study chair, click on their name and a new email window will open.

Brain

Breast

Cancer Care Delivery Research

Cancer Control and Survivorship

Trials Currently Recruiting Participants - Lymphoma Committee

STUDY	DESCRIPTION	ECOG-ACRIN STUDY CHAIR (STATISTICIAN)	ACCRUAL GOAL	DATE ACTIVATED	EDUCATIONAL MATERIALS
EA4151	A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission	Timothy S. Fenske, MD, MS, Chair (Fangxin Hong, PhD)	689	08/29/2017	EA4151 Resources
EA4181	A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma	Nina Wagner-Johnston, MD (Opeyemi Jegede, MS, Fenghai Duan, PhD)	369	10/03/2019	EA4181 Resources
E4412	A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma	Catherine M. Diefenbach, MD, Chair Stephen M. Ansell, MD, PhD, Co-Chair (Fangxin Hong, PhD)	190	01/24/2014	E4412 Resources

STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
(STATISTICIAN) ACCRUAL
GOAL DATE
ACTIVATED EDUCATIONAL MATERIALS

EA4151 A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission Timothy S. Fenske, MD, MS, Chair
(Fangxin Hong, PhD) 689 08/29/2017 EA4151 Resources

EA4181 A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma Nina Wagner-Johnston, MD
(Opeyemi Jegede, MS, Fenghai Duan, PhD) 369 10/03/2019 EA4181 Resources

E4412 A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Catherine M. Diefenbach, MD,
Chair
Stephen M. Ansell, MD, PhD, Co-Chair
(Fangxin Hong, PhD) 190 01/24/2014 E4412 Resources

Download